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A R T I C L E   I N F O S U M M A R Y 
New regulations regarding elemental impurities in pharmaceuticals will be 
implemented in January 2018 and the guidelines include the use of inductively 
coupled plasma optical emission spectroscopy (ICP-OES) and inductively coupled 
plasma mass spectrometry (ICP-MS). In this work, a method using each instrument 
was developed for the analysis of arsenic (As), cadmium (Cd), mercury (Hg), lead 
(Pb), cobalt (Co), nickel (Ni) and vanadium (V) and validated to meet the 
international conference of harmonisation (ICH Q3D) guidelines. Liquid and solid 
samples were prepared using microwave assisted acid digestion method that was 
developed using reverse aqua regia. The results obtained from the validation 
showed good linearity (R2>0.995) with low limits of detections (LODs) and limits 
of quantifications (LOQs). The percentage recoveries for both the standard 
reference material (SRM) and the spiked samples were between 95-105% with 
relative standard deviation (RSD) of less than 5. Cold symptoms relief products 
were purchased and analysed. Levels of Pb and Cd in certain products were found 
to exceed the permitted daily exposure limit (PDE) when the maximum dose was 
taken. 
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INTRODUCTION 
Elemental impurities in pharmaceutical products are 
of great concern, since they do not have a therapeutic 
benefit and some contaminants have inherent 
toxicity. In addition, these elements may have 
adverse effects on the pharmaceutical active 
ingredient stability and shelf life by catalysing the 
degradation of drug substances. 
The United States Pharmacopeia (USP) method, USP 
231 proved to be unreliable, so new regulations 
regarding elemental impurities in pharmaceutical 
products using techniques like inductively coupled 
plasma optical emission spectroscopy (ICP-OES) and 
inductively coupled plasma mass spectrometry (ICP- 
MS) were introduced in the USP Chapters 232 and 
233 as well as the International Conference of 
Harmonisation (ICH Q3D) guidelines which will be 
introduced in all pharmaceutical products in January 
2018. In the new guidelines, the allowed elemental 
impurities limits differ for different routes of 
administration; oral, parenteral or inhalation and are 
expressed as permitted daily exposure (PDE) doses 
in µg (of element)/day. 
MATERIALS AND METHODS 
Trace metal grade nitric acid (67-69% HNO3) and 
hydrochloric acid (34-37% HCl) were used for all 
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experiments (Fisher Scientific, UK). Elements 
standards for ICP-OES and ICP-MS 1000 µg/mL 
each (SCP Science, EU) were used for calibration. 
Ultrapure water with a resistivity of 18 MΩ cm was 
obtained using TripleRed water purification system 
(TripleRed laboratory technology, UK). Standard 
reference material, SRM 3280 Multivitamin 
/Multielement tablets (National Institute of 
Standards and Technology, USA) was used to 
validate the method. Cold symptoms relief remedies 
were purchased from local retail outlets. For samples 
preparation, Mixer Mill MM200 (Retsch®) was used 
to grind the tablets and for microwave assisted acid 
digestion SP-D Microwave (CEM®) was used with 
35 mL Pyrex® vessels. Elemental analysis was 
performed using: 1) ICP-OES (Thermo® iCAP 6500 
Duo), 2) ICP-MS (Thermo® X series) both with 
standard nebuliser, spray chamber and fittings. The 
instrument’s optimisation was performed by 
comparing signals and signal to blank ratios to get 
settings with the best sensitivity for each of the 
elements. 
RESULTS AND DISCUSSION 
The optimised and validated methods showed good 
linearity (R2>0.995) over a wide range with low 
limits of detection (LODs) and limits of 
quantification (LOQs) as shown in Table 1. The 
percentage recoveries for both the standard reference 
material (SRM) and the spiked samples were 
between 95-105% with relative standard deviation 
(RSD) of less than 5. When commercially available 
cold relief products were analysed, six products had 
Pb levels exceeding the permitted daily exposure 
limit (PDE) when the maximum dose is taken and 
four products contain Cd in concentrations that 
exceed the ICH Q3D PDE, which is 5 µg/day for 
both elements. Other elements were also quantified 
in some of products including Hg, Co and Ni, but 
were within the PDEs. See Table 2. 
Table 1. LODs and LOQs (ng/ml) obtained using ICP-OES / ICP-MS. 
Element 
ICP-OES  ICP-MS (Standrd Mode) ICP-MS Collision/Reaction cell (CCT Mode) 
LOD LOQ LOD LOQ LOD LOQ 
As 1.95 5.86 0.73 2.1 0.05 0.15 
Cd 0.29 0.87 0.04 0.09 0.01 0.03 
Hg 0.8 2.3 0.59 1.83 0.57 1.7 
Pb 1.56 4.73 0.07 0.2 0.02 0.05 
Co 0.77 1.58 0.08 0.22 0.09 0.29 
Ni 0.74 1.72 0.2 0.59 0.07 0.23 
V 2.75 7.64 6.33 19.06 0.15 0.48 
Table 2. Elemental impurities in cold relief remedies (mean ± σ, n=3) 
Element Product 1 Product 2 Product 2 Product 4 Product 5 Product 6 Product 7 
As <LOD <LOD <LOD <LOD <LOD <LOD <LOD 
Cd 0.55 ± 0.09 6.19 ±2.3 <LOD 2.22 ±0.48 7.23 ±4.2 9.69 ±2.2 7.56 ±0.59 
Hg <LOD <LOD 16.87 ±3.1 <LOD 9.01 ±2.7 <LOD <LOD 
Pb 4.14  ± 0.52 22.68 ±4.3 35.89 ±3.8 7.79 ±1.9 20.24 ±5.1 25.84 ±1.0 37.29 ±2.6 
Co <LOD 17.86 ±2.4 11.44 ±4.7 42.63 ±3.9 6.02 ± 2.1 9.13  ± 4.8 42.63 ±3.9 
Ni <LOD 13.67 ±2.0 21.86 ±2.5 2.70 ±1.0 10.01 ±2.0 14.45 ±1.1 35.69 ±6.4 
V <LOD <LOD <LOD <LOD <LOD <LOD <LOD 
 
CONCLUSIONS 
From the validated results obtained using ICP-OES 
and ICP-MS it can be concluded that both techniques 
are suitable for the determination of elemental 
impurities in pharmaceutical products. 
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